All In Biotech

Drug Trial Radar · NCT07020988

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Jun 12, 2025

Primary completion

Jan 6, 2026

Study completion Jan 21, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).

Conditions

  • Healthy Participants

Interventions

  • Staccato AlprazolamDrug

    Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.

  • MidazolamDrug

    Study participants will receive single dose of IV Midazolam at pre-specified time points.

  • DiazepamDrug

    Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of Staccato alprazolam in Group 1Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1
  2. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of iv midazolam in Group 1Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Up0127 1001

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.